Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk

Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.